arrow

MedicoRX and VascoRX are now AleraCare

Advancing Care. Enhancing Lives.

August 2024

Kisunla™ – New FDA-Approved Alzheimer’s Treatment Now Available at AleraCare

We are thrilled to announce that AleraCare’s Scottsdale, AZ Ambulatory Infusion Center has become one of the first facilities in the nation to administer Kisunla™

Kisunla™ (donanemab-azbt), the latest FDA-approved treatment for early-stage Alzheimer’s disease. Our patient’s journey was notably featured on Arizona’s NBC 12 and CBS 5, bringing national attention to AleraCare’s commitment to being at the forefront of innovative healthcare solutions to patients.

Overview of Kisunla™

Kisunla, recently approved by the U.S. Food and Drug Administration (FDA), represents a groundbreaking advancement in Alzheimer’s therapy. It is specifically indicated for adults with early symptomatic Alzheimer’s disease, including those experiencing mild cognitive impairment (MCI) or mild dementia. Kisunla is unique in its ability to target and remove amyloid plaques—key contributors to the progression of Alzheimer’s. Once the amyloid plaques are sufficiently cleared, the treatment can be stopped, which may result in fewer infusions and reduced overall costs for patients.

AleraCare’s Commitment to Transformative Care
  • Leadership in Innovation: We have solidified our position as a leader in administering advanced therapies. Being one of the first to introduce Kisunla aligns with our mission to offer the most effective and compassionate care to our patients.
  • Next Steps: Following our success in Scottsdale, we have now treated the first patient in California. This represents our ongoing commitment to making Kisunla accessible to more patients
  • Patient-Centered Care: Our 98.8% patient satisfaction rate reflects the high standard of care that we uphold. Kisunla’s introduction is another step in our continuous efforts to improve patient care and outcomes.
Support for Our Patients

Medicare provides coverage for eligible patients receiving Kisunla, ensuring broader access to this revolutionary treatment. At AleraCare, we provide the highest level of support through resources and services such as coverage determination, clinical review, investigation of financial assistance, and scheduling that make our patients’ infusion treatment positive and effective. Additionally, Eli Lilly offers comprehensive support through its Lilly Support Services program.